MLAB at a glance
MESA LABORATORIES INC /CO/ (MLAB, SEC CIK 724004) filed its latest 10-K annual report on June 3, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as October 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended March 31, 2026 (FY2026), MESA LABORATORIES INC /CO/ (MLAB) reported revenue of $249.1 million (up 3.4% from FY2025) and net income of $6.7 million. Diluted EPS was $1.21.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding MESA LABORATORIES INC /CO/ (MLAB) shares worth $266.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $249.1M
- +3.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $266.0M · +0 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material risk-factor changes during quarter, per filing
- Carried-forward risks remain those disclosed in March 31, 2026 Form 10-K
- Credit agreement amended September 16, 2026, indicating potential financing-risk developments
- New share repurchase program approved November 4, 2026, after quarter-end, affecting capital-allocation risk
AI summary of the MLAB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Mesa Laboratories’ fiscal Q2 and first-half results through September 30, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, margins, guidance and segment performance details
Item EX-99.1: Item EX-99.1
- 2Q27 revenue $62.3M, up 2.6%; adjusted EBITDA $17.3M, margin 27.8% versus 23.5%, signaling substantial operating leverage
- SDC revenue rose 14.6% to $25.3M, while BPD and Clinical Genomics declined 8.2% and 8.8%, respectively
Item 2.05: Costs Associated with Exit or Disposal Activities
- Approximately 40 positions eliminated, primarily in Clinical Genomics, signaling a narrower focus on pharmacogenomics, oncology and high-utilization accounts
- Hamburg, Germany facility exit targeted for February 2027 lease expiration
Item 7.01: Regulation FD Disclosure
- Press release announces Mesa Laboratories’ Restructuring Program
- Exhibit 99.1 contains the program details, including expected scope and financial impact
Item 5.07: Submission of Matters to a Vote of Security Holders
- Annual meeting quorum: 4,872,692 of 5,595,869 eligible shares represented
- All seven director nominees reelected to one-year terms through 2027 annual meeting
AI summaries of MLAB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MLAB
Don't miss the next MLAB filing
- Alerts as it files. A push when MLAB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MLAB, by share count.
- Ask anything. An AI agent that reads every MLAB filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sullivan John James | G | Oct 13, 2026 | 1,200 | - |
| Ladiwala Shiraz Shabanali | A | Sep 9, 2026 | 2,510 | - |
| Hall Shannon | A | Sep 9, 2026 | 1,774 | - |
| Sullivan John James | A | Sep 9, 2026 | 1,774 | - |
| Capone Mark Christopher | A | Sep 9, 2026 | 2,423 | - |
| Tripeny R Tony | A | Sep 9, 2026 | 1,774 | - |
| Tripeny R Tony | M | Aug 15, 2026 | 2,784 | - |
| Sullivan John James | M | Aug 15, 2026 | 2,784 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $241.0M | $249.1M |
| Gross Profit | - | $150.9M | $158.3M |
| Operating Income | - | $16.3M | $18.5M |
| Net Income | - | -$2.0M | $6.7M |
| Gross Margin | - | 62.6% | 63.5% |
| Op. Margin | - | 6.8% | 7.4% |
| Net Margin | - | -0.8% | 2.7% |
| Balance Sheet | |||
| Total Assets | $446.8M | $433.3M | $427.7M |
| Equity | $145.4M | $159.8M | $186.2M |
| ROE | - | -1.2% | 3.6% |
| Per Share | |||
| EPS | - | $-0.36 | $1.21 |
| Cash Flow | |||
| Operating CF | - | $46.8M | $42.8M |
| CapEx | - | $4.2M | $3.3M |
Source: XBRL data in MESA LABORATORIES INC /CO/ (MLAB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MLAB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $266.0M |
| Q2 2026 | 27 | $208.4M |
| Q1 2026 | 27 | $158.8M |
| Q4 2025 | 25 | $135.2M |
| Q3 2025 | 27 | $119.2M |
| Q2 2025 | 28 | $234.6M |
| Q1 2025 | 24 | $203.9M |
| Q4 2024 | 21 | $184.5M |
- Two Sigma Investments+90.2K (+309%)
- D.E. Shaw & Co+45.8K (+56%)
- Raymond James Financial+25.1K (+17%)
- Principal Financial Group+18.4K (+152%)
- BlackRock+17.0K (+4%)
- AQR Capital Management−74.6K (-37%)
- Citadel Advisors LLC−31.6K (-88%)
- Bank of America Corp−29.1K (-58%)
- Goldman Sachs Group−19.1K (-30%)
- Morgan Stanley−17.0K (-11%)
- Ameriprise Financial+18.1K
- Prudential Financial+1.9K
- FMR LLC (Fidelity)−88.9K
- Renaissance Technologies LLC−28.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 206 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MLAB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Oct 29, 2026 | - | - | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
Related Industrials companies
- AME · AmetekIndustrial Instruments For Measurement, Display, and Control
- FTV · FortiveIndustrial Instruments For Measurement, Display, and Control
- RAL · Ralliant CorpIndustrial Instruments For Measurement, Display, and Control
- ROP · Roper TechnologiesIndustrial Instruments For Measurement, Display, and Control
- MMM · 3MSurgical & Medical Instruments & Apparatus
- AOS · A. O. SmithHousehold Appliances
- AIR · AAR CORPAircraft & Parts
- ABM · ABM INDUSTRIES INC /DE/Services-To Dwellings & Other Buildings
MLAB SEC filings: frequently asked questions
Which institutions hold MLAB stock?
As of September 30, 2026, the largest MESA LABORATORIES INC /CO/ (MLAB) holders among the 13F filers tracked by SignalX were BlackRock ($59.5 million), Vanguard Capital Management LLC ($30.7 million), Raymond James Financial ($22.8 million), Dimensional Fund Advisors ($21.3 million), Morgan Stanley ($18.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MLAB's revenue in fiscal year 2026?
For the fiscal year ended March 31, 2026 (FY2026), MESA LABORATORIES INC /CO/ (MLAB) reported revenue of $249.1 million (up 3.4% from FY2025) and net income of $6.7 million. Diluted EPS was $1.21. The figures come from the XBRL data in the 10-K.
What did MLAB report in its latest 8-K?
MESA LABORATORIES INC /CO/ (MLAB) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Mesa Laboratories’ fiscal Q2 and first-half results through September 30, 2026.
What are the latest MLAB SEC filings?
MESA LABORATORIES INC /CO/ (MLAB) filed its latest 10-K annual report on June 3, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on October 29, 2026.
What is MLAB's SEC CIK number?
MESA LABORATORIES INC /CO/ (MLAB)'s SEC Central Index Key (CIK) is 724004. EDGAR lists every MLAB filing under that number.
Ask anything about MLAB
The research agent reads MLAB's filings, financials, insider trades and 13F holders, then answers with sources.